What the label lists and what reports show
Anhydrous citric acid and magnesium oxide and sodium picosulfate side effects
Anhydrous citric acid and magnesium oxide and sodium picosulfate's FDA label: “Most common adverse reactions are: Adults (≥2%): nausea, headache, hypermagnesemia, abdominal pain and dehydration or dizziness.” FAERS holds 722 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is nausea (107 reports).
- No generic listed
Check it at the source: the anhydrous citric acid and magnesium oxide and sodium picosulfate FDA label on DailyMed (effective April 15, 2026); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of CLENPIQ?CLENPIQ can cause serious side effects, including: See " What is the most important information I should know about CLENPIQ"? Changes in certain blood tests. Your healthcare provider may do blood tests after you take CLENPIQ to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including: vomiting stomach area (abdominal) cramping seizures nausea urinate less than usual fainting bloating trouble drinking clear liquids heart problems dizziness troubles swallowing Ulcers of the bowel or bowel problems (ischemic colitis). Tell your healthcare provider right away if you have severe stomach-area (abdominal) pain or rectal bleeding. […]
Source: FDA drug label, Ferring Pharmaceuticals Inc., effective April 15, 2026 (SPL set e95fff66-4ec0-4001-a727-33e66a5ec7d5), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions are: Adults (≥2%): nausea, headache, hypermagnesemia, abdominal pain and dehydration or dizziness.
Table 1: Common Adverse Reactions Observed in at Least 2% of Patients Undergoing Colon Cleansing in Study 1
| Reaction | Adverse Reaction CLENPIQ (N=448) % | Split-Dose Regimen Sodium picosulfate, magnesium oxide, and anhydrous citric acid Powder for reconstitution… |
|---|---|---|
| Nausea | 3 | 3 |
| Headache | 3 | 3 |
| Hypermagnesemia Magnesium levels returned to normal within one week after colonoscopy in… | 2 | 5 |
| Abdominal pain Abdominal pain included reports of abdominal pain, abdominal pain upper,… | 2 | 2 |
| Dehydration or dizziness | 2 | 2 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling: Serious Fluid and Electrolyte Abnormalities [see Warnings and Precautions (5.1) ] Seizures [see Warnings and Precautions (5.2) ] Use in Patients with Renal Impairment [see Warnings and Precautions (5.3) ] Cardiac Arrhythmias [see Warnings and Precautions (5.4) ] Syncope [see Warnings and Precautions (5.5) ] Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis [see Warnings and Precautions (5.6) ] Use in Patients with Significant Gastrointestinal Disease [see Warnings and Precautions (5.7) ] Aspiration [see Warnings and Precautions (5.8) ] Most common adverse reactions are: Adults (≥2%): nausea, headache, hypermagnesemia, abdominal pain and dehydration or dizziness. ( 6.1 ) Pediatrics 9 to 16 years (>5%): nausea, vomiting, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. …
Source: FDA drug label, Ferring Pharmaceuticals Inc., effective April 15, 2026 (SPL set e95fff66-4ec0-4001-a727-33e66a5ec7d5), via openFDA; the full label on DailyMed
What do FAERS reports show?
722 reports list anhydrous citric acid and magnesium oxide and sodium picosulfate among the medicines taken, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 40 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 19 reactions below, 8 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Anhydrous citric acid and magnesium oxide and sodium picosulfate: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions